ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway

Keyphrases

• Next-generation Sequencing 100%
• Genomic Landscape 100%
• Cholangiocarcinoma 100%
• Biliary Tract Carcinoma 100%
• Targetable 100%
• ERBB2 100%
• Anti-HER2 Agents 66%
• Clinical Outcomes 33%
• Aberrations 33%
• Chemotherapy 33%
• High Prevalence 33%
• Clinical Significance 33%
• Point mutation 33%
• Tissue Sampling 33%
• Poor Outcome 33%
• Clinical Benefit 33%
• Liquid Biopsy 33%
• Targeted Therapy 33%
• Trastuzumab 33%
• Patient Cohort 33%
• Somatic Aberrations 33%
• Chemotherapy Regimen 33%
• Median Overall Survival 33%
• Disease Stabilization 33%
• Extrahepatic Cholangiocarcinoma 33%
• EGFR Pathway 33%
• Copy number Amplification 33%
• Neratinib 33%
• Targetable Alterations 33%
• Everyday Practices 33%
• Intrahepatic Cholangiocarcinoma (iCCA) 33%

Medicine and Dentistry

• Cholangiocarcinoma 100%
• Next Generation Sequencing 50%
• Genetics 50%
• Epidermal Growth Factor Receptor 33%
• Chemotherapy 33%
• Prevalence 16%
• Somatics 16%
• Point Mutation 16%
• Clinical Significance 16%
• Overall Survival 16%
• Liquid Biopsy 16%
• Targeted Therapy 16%
• Trastuzumab 16%
• Neratinib 16%
• Diseases 16%